Subtype
Liver Neoplasm
CI-CAN-00001077Explore in graph →
Non-malignant930 active trials14 approved drugs17 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001077Explore in graph →
Clinical trials
4,334 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03898921 | RFA vs. SBRT for Small HCC | unknown | Phase 3 | 270 | Sun Yat-sen UniversityOTHER | 1 | Nov 24, 2020 | clinicaltrials |
| NCT03766633 | Accuracy of the LiverVision® Semi-automated Liver Volumetry Software(LiverVision) | unknown | — | 108 | Royal Free Hospital NHS Foundation TrustOTHER | 3 | Nov 20, 2020 | clinicaltrials |
| NCT04627363 | HAIC Combined With Bevacizumab and Toripalimab for Advanced Hepatocellular Carcinama | unknown | Phase 2 | 30 | Sun Yat-sen UniversityOTHER | 0 | Nov 13, 2020 | clinicaltrials |
| NCT04317248 | "Cocktail" Therapy for Hepatitis B Related Hepatocellular Carcinoma | unknown | Phase 2 | 600 | Yuehua HuangOTHER | 1 | Oct 29, 2020 | clinicaltrials |
| NCT02046356 | Recurrence Risk Factors of Early-Stage Hepatocellular Carcinoma After Radio Frequency Ablation | unknown | — | 139 | Yunhua TanOTHER | 1 | Oct 26, 2020 | clinicaltrials |
| NCT04181931 | Neo-TACE-HAIC for PVTT-HCC(NeoconceptC) | unknown | N/A | 320 | Sun Yat-sen UniversityOTHER | 1 | Oct 26, 2020 | clinicaltrials |
| NCT04424043 | Neo-TACE-HAIC for BCLC B Stage HCC(NeoconceptB) | unknown | N/A | 280 | Sun Yat-sen UniversityOTHER | 1 | Oct 26, 2020 | clinicaltrials |
| NCT03645980 | DKN-01 Inhibition in Advanced Liver Cancer | unknown | Phase 1 / Phase 2 | 70 | Johannes Gutenberg University MainzOTHER | 1 | Oct 22, 2020 | clinicaltrials |
| NCT04597970 | TACE Plus HAIC With Oxaliplatin and Raltitrexed for BCLC Stage C HCC(OXRI) | unknown | Phase 2 | 66 | Peking University Cancer Hospital & InstituteOTHER | 0 | Oct 22, 2020 | clinicaltrials |
| NCT04076631 | Surgical Stages of Liver Cirrhosis In Patients With Hepatocellular Carcinoma | unknown | — | 1,000 | Chen XiaopingOTHER | 1 | Oct 12, 2020 | clinicaltrials |
| NCT03302403 | Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors | unknown | N/A | 18 | Kang YUOTHER | 1 | Oct 8, 2020 | clinicaltrials |
| NCT04454762 | A Study to Evaluate the Safety, Tolerability and Efficacy of Cabozantinib in Patients With Hepatocellular Carcinoma and Impaired Liver Function(CaboCHILD) | unknown | Phase 2 | 20 | Johannes Gutenberg University MainzOTHER | 1 | Oct 5, 2020 | clinicaltrials |
| NCT04550663 | NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ Tumors | unknown | Phase 1 | 10 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Sep 23, 2020 | clinicaltrials |
| NCT04560751 | TACE Combined With Lenvatinib for Unresectable Hepatocellular Carcinoma (Prolong) | unknown | — | 300 | Zhejiang Cancer HospitalOTHER | 0 | Sep 23, 2020 | clinicaltrials |
| NCT04443322 | Durvalumab and Lenvatinib in Participants With Locally Advanced and Metastatic Hepatocellular Carcinoma ( Dulect2020-1 )(Dulect2020-1) | unknown | N/A | 20 | RenJi HospitalOTHER | 1 | Sep 22, 2020 | clinicaltrials |
| NCT04552236 | Evaluation of Liver Stiffness by Ultrasound Elastography for Predicting Early HCC Recurrence After Treatment | unknown | — | 100 | Assiut UniversityOTHER | 0 | Sep 17, 2020 | clinicaltrials |
| NCT04538313 | A Clinical Study in Patients With High-risk Recurrent Primary Hepatocellular Carcinoma Using Autologous TILs | unknown | Phase 1 / Phase 2 | 40 | CAR-T (Shanghai) Cell Biotechnology Co., Ltd.NETWORK | 1 | Sep 4, 2020 | clinicaltrials |
| NCT03754192 | Perfusion and Dual Energy Computer Tomography in Hepatocellular Carcinoma(PERCAHEC) | unknown | N/A | 50 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Sep 1, 2020 | clinicaltrials |
| NCT04527679 | Cisplatin and Gemcitabine Chemotherapy and Lenvatinib for Patients With Unresectable Intrahepatic Cholangiocarcinoma | unknown | Phase 2 | 40 | Shanghai Zhongshan HospitalOTHER | 1 | Aug 26, 2020 | clinicaltrials |
| NCT04523467 | Anti-angiogenic Targeted Drugs Plus Rg3 to Improve the Efficacy of TACE for Unresectable Hepatocellular Carcinoma | unknown | N/A | 320 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Aug 21, 2020 | clinicaltrials |
| NCT04523662 | Study on the Effectiveness and Safety of Carrelizumab Combined With Apatinib Mesylate and Radiotherapy in the Treatment of Advanced Liver Cancer | unknown | Phase 2 | 27 | Beijing Tsinghua Chang Gung HospitalOTHER | 0 | Aug 21, 2020 | clinicaltrials |
| NCT04521491 | A Trial of Adjuvant Therapy After Hepatocarcinoma Resection Based on Folate Receptor-positive Circulating Tumor Cells | unknown | N/A | 184 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Aug 20, 2020 | clinicaltrials |
| NCT04518774 | Allogeneic "Gammadelta T Cells (γδ T Cells)" Cell Immunotherapy in Phase 1 Hepatocellular Carcinoma Clinical Trial | unknown | Early Phase 1 | 8 | Beijing 302 HospitalOTHER | 1 | Aug 19, 2020 | clinicaltrials |
| NCT04513119 | The Short-term Efficacy of Novel NTDP-RFA in the Treatment of Small HCC With Cirrhosis. | unknown | — | 100 | Southwest Hospital, ChinaOTHER | 1 | Aug 14, 2020 | clinicaltrials |
| NCT04506281 | PD1 Antibody (Toripalimab), GEMOX and Lenvatinib Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors | unknown | Phase 2 | 128 | Shanghai Zhongshan HospitalOTHER | 1 | Aug 10, 2020 | clinicaltrials |
| NCT04297202 | SHR-1210 Combined With Apatinib Mesylate in the Perioperative Treatment of Hepatocellular Carcinoma(HCC-009) | unknown | Phase 2 | 20 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 7, 2020 | clinicaltrials |
| NCT04494022 | Role of CEUS as a Secondary Diagnostic Modality | unknown | N/A | 120 | Seoul National University HospitalOTHER | 1 | Jul 31, 2020 | clinicaltrials |
| NCT03642561 | Evaluation the Treatment Outcome for RFA in Patients With BCLC Stage B HCC in Comparison With TACE | unknown | Phase 2 / Phase 3 | 300 | Fudan UniversityOTHER | 1 | Jul 28, 2020 | clinicaltrials |
| NCT03507998 | Phase 1 Dose Escalation Study of CGX1321 in Subjects With Advanced Gastrointestinal Tumors | unknown | Phase 1 | 39 | Curegenix Inc.INDUSTRY | 1 | Jul 24, 2020 | clinicaltrials |
| NCT02169765 | HR Versus RFA for Early Stage HCC(ARTC-HCC) | unknown | Phase 3 | 120 | Guangxi Medical UniversityOTHER | 1 | Jul 22, 2020 | clinicaltrials |
| NCT03734926 | A Phase 1 Study of ZSP1241 in Participants With Advanced Solid Tumors | unknown | Phase 1 | 90 | Guangdong Zhongsheng Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 22, 2020 | clinicaltrials |
| NCT03974074 | Albumin for Hepatocellular Carcinoma | unknown | Phase 3 | 200 | Guangxi Medical UniversityOTHER | 1 | Jul 22, 2020 | clinicaltrials |
| NCT04476641 | A Study of DC-CIK Immunotherapy in the Treatment of Solid Tumors(DC-CIK) | unknown | Phase 2 | 686 | Sun Yat-sen UniversityOTHER | 1 | Jul 20, 2020 | clinicaltrials |
| NCT04104074 | Safety and Efficacy of Radiotherapy Plus Sintilimab for HCC With Portal Vein Tumor Thrombosis | unknown | Phase 1 | 20 | Beijing Tsinghua Chang Gung HospitalOTHER | 1 | Jul 7, 2020 | clinicaltrials |
| NCT04460157 | Prediction of Liver-related Outcomes After HCV Cure | unknown | — | 1,035 | Hospital Universitario de ValmeOTHER | 1 | Jul 7, 2020 | clinicaltrials |
| NCT04411706 | A Study of Sintilimab Combined With Apatinib and Capecitabine in Advanced Hepatocellular Carcinoma | unknown | Phase 2 | 46 | Xin-Hua XuOTHER | 1 | Jun 24, 2020 | clinicaltrials |
| NCT04386772 | Portal Vein Embolization Using Coils Plus TAGM vs Multiple Coils for Patients With Perihilar Cholangiocarcinoma or Hepatocellular Carcinoma | unknown | N/A | 56 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Jun 17, 2020 | clinicaltrials |
| NCT04434989 | SBRT Versus Ablation for Perivascular Hepatocellular Carcinoma(SAIL) | unknown | N/A | 170 | Sun Yat-sen UniversityOTHER | 1 | Jun 17, 2020 | clinicaltrials |
| NCT04435977 | Efficacy and Safety of Cabozantinib in Patients With Hepatocellular Carcinoma(Immunocabo) | unknown | Phase 2 | 46 | Istituto Clinico HumanitasOTHER | 1 | Jun 17, 2020 | clinicaltrials |
| NCT02971345 | Endovascular Brachytherapy Combined With Stent Placement and TACE for HCC With Main Portal Vein Tumor Thrombus | unknown | Phase 3 | 253 | Shanghai Zhongshan HospitalOTHER | 1 | Jun 11, 2020 | clinicaltrials |
| NCT04413734 | Combination of Anti-PD-1 Antibody and Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma | unknown | Phase 2 | 120 | Zhejiang UniversityOTHER | 1 | Jun 4, 2020 | clinicaltrials |
| NCT04414956 | Combining Biomarkers (AFP, AFP-L3, and PIVKA-II) and Image Tools for Early Detection of Hepatocellular Carcinoma | unknown | N/A | 1,418 | Korea UniversityOTHER | 1 | Jun 4, 2020 | clinicaltrials |
| NCT03588442 | Prospective Surveillance for Very Early Hepatocellular Carcinoma(PRECAR) | unknown | — | 10,000 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | May 22, 2020 | clinicaltrials |
| NCT03780049 | HAIC Plus H101 vs HAIC Alone for Unresectable HCC at BCLC A-B | unknown | Phase 3 | 304 | Sun Yat-sen UniversityOTHER | 1 | May 21, 2020 | clinicaltrials |
| NCT04392700 | A RCT of TNF and ENT in the Treatment of Long-term Prognosis With Hepatitis B-related HCC After Curative Resection | unknown | Phase 3 | 706 | Sun Yat-sen UniversityOTHER | 1 | May 19, 2020 | clinicaltrials |
| NCT04368182 | AFP Specific T Cell Receptor Transduced T Cells Injection(C-TCR055) in Unresectable Hepatocellular Carcinoma | unknown | Phase 1 | 3 | Zhejiang UniversityOTHER | 1 | Apr 29, 2020 | clinicaltrials |
| NCT03592706 | Autologous Immune Killer Cells to Treat Liver Cancer Patients as an Adjunct Therapy | unknown | Phase 2 / Phase 3 | 60 | Ivy Life Sciences, Co., LtdINDUSTRY | 1 | Apr 16, 2020 | clinicaltrials |
| NCT03116984 | A Study of Comparison of TACE Combination With and Without EBRT for Advanced HCC(TACE-EBRT) | unknown | Phase 3 | 300 | Shanghai Zhongshan HospitalOTHER | 1 | Apr 10, 2020 | clinicaltrials |
| NCT03971747 | AFP Specific T Cell Receptor Transduced T Cells Injection(C-TCR055) in Unresectable Hepatocellular Carcinoma | unknown | Phase 1 | 9 | Shanghai AbelZeta Ltd.INDUSTRY | 1 | Apr 7, 2020 | clinicaltrials |
| NCT04080154 | Study of Anlotinib After Lenvatinib in Patients With Hepatocellular Carcinoma(ALTER-H-002) | unknown | Phase 2 | 28 | Shanghai Zhongshan HospitalOTHER | 1 | Apr 3, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Nov 24, 2020source: clinicaltrials